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Abstract
Cisplatin-like chemotherapeutics cause vomiting via calcium (Ca2+)-dependent release 
of multiple neurotransmitters/mediators (dopamine, serotonin, substance P, prosta-
glandins and leukotrienes) from the gastrointestinal enterochromaffin cells and/or the 
brainstem. Intracellular Ca2+ signaling is triggered by activation of diverse emetic recep-
tors (including neurokininergic NK
1
, serotonergic 5-HT
3
, dopaminergic D
2
, cholinergic 
M
1
, or histaminergic H
1
), whose stimulation in vomit-competent species evokes emesis. Other emetogens such as cisplatin, rotavirus NSP4 protein, and bacterial toxins can also 
induce intracellular Ca2+ elevation. Our findings demonstrate that application of the 
L-type Ca2+ channel (LTCC) agonist FPL 64176 and the intracellular Ca2+ mobilizing agent 
thapsigargin (a sarco/endoplasmic reticulum Ca2+-ATPase inhibitor) cause vomiting in 
the least shrew. On the other hand, blockade of LTCCs by corresponding antagonists 
(nifedipine or amlodipine) not only provide broad-spectrum antiemetic efficacy against 
diverse agents that specifically activate emetogenic receptors such as 5-HT
3
, NK
1
, D
2
, 
and M
1
 receptors, but can also potentiate the antiemetic efficacy of palonosetron against 
the nonspecific emetogen, cisplatin. In this review, we will provide an overview of Ca2+ 
involvement in the emetic process; discuss the relationship between Ca2+ signaling and 
the prevailing therapeutics in control of vomiting; highlight the current evidence for Ca2+-
signaling blockers/inhibitors in suppressing emetic behavior and also draw attention to 
the clinical benefits of Ca2+-signaling blockers/inhibitors for the treatment of nausea and 
vomiting.
Keywords: cisplatin, vomiting, antiemesis, Ca2+, L-type Ca2+ channel
1. Introduction
Acute (≤24 h) and delayed (>24 h) phases of chemotherapy-induced nausea and vomiting 
cause distressing side-effects which affect the well-being and quality of life of cancer patients 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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receiving chemotherapy, especially cisplatin [1]. Major neurotransmitter mechanisms under-
lying chemotherapy-induced nausea and vomiting have been subject of considerable research 
over the past 45 years. As presented in brief in Figure 1, cancer chemotherapeutics such as 
cisplatin evoke vomiting via local release of a variety of emetic neurotransmitters/mediators 
(including dopamine, serotonin (5-HT), substance P, prostaglandins and leukotrienes) both 
from the enterochromaffin cells of the gastrointestinal tract and the brainstem emetic loci in 
the dorsal vagal complex containing the nucleus tractus solitarius, the dorsal motor nucleus 
of the vagus and the area postrema [2–4]. The area postrema and the nucleus tractus solitarius 
contain large numbers of fenestrated capillaries which lack blood-brain barrier and permit 
neurons in both areas access to blood-borne circulating factors including emetogens [5]. The 
chemoreceptor trigger zone, in the area postrema has high concentrations of emetic receptors 
for serotonin (5-HT
3
), dopamine (D2/3), neurokinin (NK1), and opioids (μ), among others [2]. Direct stimulation of these receptors in the chemoreceptor trigger zone by emetogens is one 
important mechanism by which vomiting can occur [6]. The nucleus tractus solitarius receives 
emesis-related information from the area postrema as well as the gastrointestinal tract con-
veyed by vagal afferents. The dorsal motor nucleus of the vagus receives axonal projections 
from nucleus tractus solitarius [7] and sends emetic signals via motor efferent pathways to 
the gastrointestinal tract and modulates vomiting behaviors [2, 5, 8, 9] (Figure 1). In addi-
tion, chemotherapeutic drugs may evoke release of emetic neurotransmitters/mediators from 
the gastrointestinal tract into the blood to be directly delivered to the area postrema via a 
Figure 1. Brief illustration of the mechanisms underlying vomiting induced by chemotherapeutic agent cisplatin. 
Mechanisms underlying cisplatin-induced vomiting can be simplified as: (1) cisplatin can increase cytoplasmic Ca2+ level 
to evoke Ca2+-dependent release of emetic neurotransmitters/mediators at the brainstem emetic loci, the dorsal vagal 
complex, and subsequently activates diverse receptors and their corresponding signaling pathways. These emetic signals 
are output to the gastrointestinal tract via efferents to trigger vomiting [2, 4–9]; (2) cisplatin-induced peripheral release 
of neurotransmitters/mediators from the gastrointestinal tract into the blood can directly stimulate the dorsal vagal 
complex, activate receptors signaling pathways and trigger vomiting [2, 10]; and (3) the peripherally-released emetic 
neurotransmitters/mediators stimulate their corresponding receptors present on vagal afferents in the gastrointestinal 
tract which indirectly activate brainstem emetic nuclei and trigger vomiting [6].
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blood-borne pathway which then triggers vomiting [2, 10], and/or the released emetic neu-
rotransmitters/mediators stimulate their corresponding receptors present on vagal afferents 
in the gastrointestinal tract which indirectly activate brainstem emetic loci primarily in the 
nucleus tractus solitaries to trigger vomiting [6].
Ca2+ is not only one of the most universal and versatile signaling molecules, it is also an 
extremely important factor in both the physiology and pathology of living organisms. At rest, 
diverse cells have strict and well-regulated mechanisms to maintain low nM cytosolic Ca2+ 
levels [11]. Cytoplasmic Ca2+ concentration is a dominant factor in determining the amount of 
transmitter released from nerve terminals [12]. Thus, Ca2+ mobilization can be an important 
aspect of vomit induction since it is involved in both triggering the quantity of neurotransmit-
ter released coupled with receptor activation, as well as post-receptor excitation-transcription 
coupling mechanisms [13]. Studies using Ca2+ imaging performed in vitro in the brainstem 
slice preparation suggest that emetic agents evoke direct excitatory effects on cytosolic Ca2+ 
signals in vagal afferent terminals in the nucleus tractus solitarius which potentiate local 
neurotransmitter release [5, 14, 15]. Therefore, chemotherapeutics including cisplatin seem to 
activate emetic circuits through a number of neurotransmitters released in a Ca2+-dependent 
Figure 2. Overview of evidence for suppression of Ca2+ signaling involved in anti-vomiting actions of antiemetic agents. 
(1) Netupitant and palonosetron are highly selective respective antagonists of NK
1
Rs and 5-HT
3
Rs are approved to 
treat the acute- and delayed- phases of chemotherapy-induced nausea and vomiting (CINV) in cancer patients [79–82]. 
Our studies [83–86] indicate that suppression of Ca2+ signaling is involved in antiemetic efficacy of both palonosetron 
and netupitant. (2) Cannabinoids such as delta-9-tetrahydrocannabinol exert their antiemetic efficacy via direct 
activation of CB
1
 receptors (CB
1
R) [92, 94, 98–100]. The ability of CB
1
R agonists to suppress both extracellular Ca2+ influx 
[111–115] and intracellular Ca2+ release from the sarco/endoplasmic reticulum stores [15, 117], result in inhibition of 
Ca2+-dependent neurotransmitter release [108] and is probably the fundamental mechanisms underlying the antiemetic 
efficacy of CB
1
R cannabinoid agonists against CINV [95–97]. (3) Glucocorticoids such as dexamethasone reduce both 
acute and delayed CINV [6]. Glucocorticoids’ ability to decrease the abnormal elevation of cytosolic Ca2+ concentration 
[122], and subsequently control Ca2+-dependent neurotransmitter release [6, 121, 126] and inflammatory responses [6]. 
Increased release of endocannabinoids and subsequent CB
1
R activation may also be involved in antiemetic actions of 
glucocorticoids [123–125]. (4) The L-type Ca2+ channel (LTCC) antagonist flunarizine can reduce cyclic vomiting in 
patients [151, 152]. Gabapentin binds to the alpha-2/delta auxiliary subunits of LTCCs, and exerts inhibitory actions on 
trafficking and activation kinetics of LTCCs [153]. Gabapentin can be used as an anti-nausea and antiemetic agent in 
postoperative nausea and vomiting [154, 155] and in CINV [156, 157]. (5) LTCC antagonists (nifedipine and amlodipine) 
are broad-spectrum antiemetics when delivered systemically against diverse specific and nonselective emetogens. 
(6) Suppression of intracellular Ca2+ release from the sarco/endoplasmic reticulum through the inositol trisphosphate 
receptors (IP
3
Rs) and ryanodine receptors (RyRs) may be additional targets for the prevention of nausea and vomiting, 
since functional and physical linkages between Ca2+ channels on cell membrane and IP
3
Rs/RyRs play a role in Ca2+ 
signaling [160–166]. In the least shrew emesis model, the RyRs antagonist dantrolene can potentiate the antiemetic 
efficacy of amlodipine against 5-HT
3
R agonist 2-Methyl-5-HT-induced vomiting [25]; and dantrolene together with the 
IP
3
R antagonist 2-APB can potentiate the antiemetic efficacy of nifedipine against thapsigargin-induced vomiting [70].
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manner in specific vomit-associated neuroanatomical structures. In both the periphery and 
the brainstem, emetic neurotransmitters/mediators—such as acetylcholine, dopamine, 5-HT, 
substance P, prostaglandins, leukotrienes, and/or histamine—may act independently or in 
combination to evoke vomiting after cisplatin administration [16] (Figure 1). In this review, 
we focus on the current evidence supporting the significance of Ca2+ signaling in emesis gen-
eration and its relationship to antiemetic efficacy, as well as the corresponding development 
of potential novel antiemetic medications, as shown in brief in Figure 2.
2. Emerging roles of Ca2+ in emesis
2.1. Emetic receptor stimulation increases intracellular Ca2+ concentration
Excitatory receptor activation by corresponding agonists can increase cytosolic Ca2+ levels 
via both mobilization of intracellular Ca2+ stores (e.g., endoplasmic reticulum = ER) and 
influx from extracellular fluid [17]. The evoked cytoplasmic Ca2+ increase may result from 
direct activation of ion channels, or indirectly via signal transduction pathways following G 
protein-coupled receptor activation. The neurokinin NK1 receptor (NK
1
R) is a member of the 
tachykinin family of G-protein-coupled receptors. NK
1
R stimulation by substance P or cor-
responding selective agonists such as GR73632, can increase cytosolic Ca2+ concentration. In 
fact GR73632-induced activation of NK
1
Rs can evoke intracellular Ca2+ release from the sarco/
endoplasmic reticulum stores via Gα/q-mediated phospholipase C pathway, which subse-
quently evokes extracellular Ca2+ influx through L-type Ca2+ channels (LTCCs) [17–19]. The 
serotonergic 5-HT
3
 receptor (5-HT
3
R) is a Ca2+-permeable ligand-gated ion channel [20]. Cell 
lines studies have demonstrated that activation of 5-HT
3
Rs by 5-HT or its analogs can evoke 
extracellular Ca2+ influx into cells in a manner sensitive to both 5-HT
3
R antagonists (tropise-
tron, MDL7222, metoclopramide) and LTCC blockers (verapamil, nimodipine, nitrendipine) 
[20–24]. These studies suggest that both L-type- and 5-HT
3
-receptor Ca2+-permeable ion chan-
nels are involved in extracellular Ca2+ influx evoked by 5-HT
3
R agonists. Moreover, 5-HT
3
R 
activation indirectly causes release of Ca2+ from ryanodine-sensitive intracellular Ca2+ stores 
subsequent to the evoked extracellular Ca2+ influx which greatly amplifies the cytoplasmic 
concentration of Ca2+ [23]. In fact, our findings from behavioral studies in the least shrew 
emesis model [25] further support the notion of Ca2+-induced Ca2+ release following 5-HT
3
R 
stimulation, which will be discussed in more detail in Section 3.4. Other emetogens such as 
agonists of dopamine D
2
- [26, 27], cholinergic M
1
- [28, 29], histaminergic H
1
- [30, 31], and 
opiate μ- [32, 33] receptors, as well as cisplatin [34], prostaglandins [35, 36], rotavirus NSP4 
protein [37, 38] and bacterial toxins [39, 40] also possess the potential to mobilize Ca2+ which 
involve extracellular Ca2+ influx and/or Ca2+ release from intracellular Ca2+ pools. Much of the 
discussed evidence has been acquired from isolated cells.
The least shrew is an emesis-competent mammal whose reactions to common emetogens are 
well-defined and correlate closely with human responses [2]. 2-Methyl-5-HT is a well-known 
selective emetic agonist targeting the emesis-prone 5-HT
3
Rs [4]. This vomit-competent species 
is an excellent animal model for studying the emetic activity of diverse agents [2]. In fact least 
shrews exhibit dose-dependent full emetic responses to intraperitoneal administration of 
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both the peripherally-acting 5-HT, as well as to its central nervous system-penetrating analog, 
2-Methyl-5-HT [4, 41, 42]. In our studies, incubation of least shrew brainstem slices contain-
ing the dorsal vagal complex emetic loci with 2-Methyl-5-HT, results in a rapid increase in 
intracellular Ca2+ concentration as reflected by an increase in fluo-4 AM fluorescence intensity 
in a palonosetron (a 5-HT
3
R antagonist)/nifedipine-sensitive manner [22, 25].
2.2. Emetic potential of Ca2+ channel activators: behavioral and 
immunohistochemical evidence
A variety of Ca2+-permeable ion-channels mediating extracellular Ca2+ influx are present in the 
plasma membrane. Among them are voltage-gated LTCCs, which can be activated by mem-
brane depolarization, and serve as the principal route of Ca2+ entry in electrically excitable cells 
such as neurons and muscle [43, 44]. Recently we have acquired direct evidence for the proposal 
that Ca2+ mobilization is an important facet in the mediation of emesis. In fact we have identified 
the novel emetogen FPL64176 (Figure 2), a selective agonist of LTCCs, which causes vomiting 
in the least shrew in a dose-dependent manner [45, 46]. All tested shrews vomited at a 10 mg/kg 
dose of FPL64176 administered intraperitoneally (i.p.). LTCCs have been shown to be present 
in enterochromaffin cells of guinea pig and human small intestinal crypts [47]. Furthermore, in 
these cells FPL64176 not only can enhance cytosolic Ca2+ concentration, but also increases 5-HT 
release from enterochromaffin cells [47]. The latter findings may have underpinnings for the 
mechanisms underlying FPL64176-evoked vomiting observed in least shrew model of emesis. 
FPL64176 (10 mg/kg., i.p.) can cause Ca2+-dependent 5-HT release from shrew intestinal entero-
chromaffin cells which in turn could increase vagal afferent activity via stimulation of 5-HT
3
 
receptors, thereby indirectly triggering emetic signals in the brainstem [2, 48].
Our most recent work has focused on the Ca2+-mobilizing agent thapsigargin (Figure 3), a 
specific and potent inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump 
which transports the free cytosolic Ca2+ into the lumen of the sarco/endoplasmic reticulum to 
Figure 3. A schematic representation of extracellular Ca2+ influx and intracellular Ca2+ release contributing to 
thapsigargin-elicited Ca2+ mobilization. Intracellular Ca2+ release from the sarco/endoplasmic reticulum (SER) Ca2+ stores 
through the inositol triphosphate receptors (IP
3
Rs) and ryanodine receptors (RyRs) is counter-balanced by continuous 
Ca2+ uptake from the cytoplasm into SER stores by the SER Ca2+-ATPase pump (SERCA). Thapsigargin is a specific 
inhibitor of SERCA and thus enhances cytosolic levels of Ca2+, a process involving SER Ca2+ release via IP
3
Rs and RyRs 
as well as extracellular Ca2+ entry through Ca2+ channels located in the plasma membrane including store-operated Ca2+ 
channels (SOCE) and L-type Ca2+ channels (LTCCs) [49–60].
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counter-balance the cytosolic intracellular Ca2+ release from the sarco/endoplasmic reticulum 
into the cytoplasm via the inositol trisphosphate receptors (IP
3
Rs) and ryanodine receptors 
(RyRs) [49–51]. Thapsigargin also causes intracellular release of stored Ca2+ from the sarco/
endoplasmic reticulum into the cytosol which subsequently evokes extracellular Ca2+ influx 
predominantly through store-operated Ca2+ entry (SOCE) in non-excitable cells [52–54]. In 
total, these events lead to a significant rise in the free concentration of cytosolic Ca2+ [55–57]. 
In addition, a partial involvement of LTCCs in thapsigargin-evoked contraction has also been 
demonstrated in rat stomach smooth muscle cells [58], rat gastric smooth muscle [59], and 
cat gastric smooth muscle [60]. On the other hand, the potential of thapsigargin as a Ca2+-
modulating cancer chemotherapeutic agent has been evaluated in both cells and animal models 
[61]. Thapsigargin-evoked increases in cytosolic Ca2+ concentration can lead to cell apoptosis, 
which can result in eradication of cancer cells of the breast [62], prostate [63], colon [64] and kid-
neys [65]. Clinically, a prodrug form of thapsigargin, mipsagargin, is currently under clinical 
trial as a targeted cancer chemotherapeutic agent with selective toxicity against cancer cells in 
tumor sites with minimal side-effects to the host [66–69]. In our studies, intraperitoneal admin-
istration of thapsigargin (0.1–10 mg/kg) caused vomiting in least shrews in a dose-dependent, 
but bell-shaped manner, with maximal efficacy at 0.5 mg/kg. An important consideration for 
the emetic potential of thapsigargin is that it augments the cytosolic levels of free Ca2+ in emetic 
loci as a result of SERCA inhibition as indicated in our latest discussed finding [70], which is the 
first study to reflect emesis as a major side-effect of thapsigargin when delivered systemically.
c-Fos induction has been used to evaluate differential neuronal activation [71]. Our lab has 
applied immunostaining and detected c-Fos induction in the brainstem emetic nuclei to 
demonstrate central responsiveness to peripheral administration of a variety of emetogens 
[4, 70, 72, 73]. The participation of the central emetic neurons in FPL64176-induced vomiting 
is further indicated by evoked c-Fos expression in brainstem emetic nuclei, the nucleus tractus 
solitarius and the dorsal motor nucleus of the vagus (unpublished data). Thus, the blood-
brain barrier permeable agent FPL64176 [74–76] could excite emetic neurons directly in the 
nucleus tractus solitarius and the dorsal motor nucleus of the vagus. Thapsigargin (0.5 mg/kg) 
also causes increases in c-Fos immunoreactivity in the brainstem emetic nuclei including the 
area postrema, the nucleus tractus solitarius and the dorsal motor nucleus of the vagus [70].
3. Ca2+ intervention mechanisms relevant to antiemetic approaches
3.1. Receptor antagonist antiemetic regimens such as netupitant/palonosetron 
(NEPA)
The ultimate aim of prophylactic management of chemotherapy-induced nausea and vomit-
ing is to abolish both the acute- and delayed phases of vomiting which will help to improve 
the well-being and quality of life of cancer patients receiving chemotherapy. Cisplatin-like 
chemotherapeutics cause release of multiple emetogenic neurotransmitters in both the central 
nervous system and the gastrointestinal tract and no available single antiemetic administered 
alone can provide complete efficacy. Significant initial work had suggested that while activa-
tion of 5-HT
3
Rs by serotonin in the gastrointestinal tract is involved in the mediation of acute 
phase of chemotherapy-induced nausea and vomiting, the delayed phase is due to stimulation 
Calcium and Signal Transduction114
of NK
1
Rs subsequent to release of substance P in the brainstem [77, 78]. However, our more 
recent findings suggest that 5-HT and substance P are concomitantly involved in both emetic 
phases in the gastrointestinal tract as well as in the brainstem [2, 16]. While netupitant is 
a highly selective and a longer-acting second generation NK
1
R antagonist, palonosetron is 
considered as a second generation 5-HT
3
R antagonist with a unique antiemetic profile in both 
humans [79, 80] and the least shrew model of emesis [45]. A successful regimen of an oral 
fixed combined dose of netupitant/palonosetron (NEPA) (Figure 2) has been formulated with 
over 85% clinical efficacy, good tolerability, and high central nervous system penetrance for 
the prophylactic treatment of acute and delayed chemotherapy-induced nausea and vomiting 
in cancer patients receiving chemotherapy [9, 81, 82].
Recent evidence accumulated from HEK293 cells stably transfected with 5-HT
3
Rs suggest that 
suppression of Ca2+ signaling is involved in antiemetic efficacy of both palonosetron and netu-
pitant. Indeed, Rojas et al. [83, 84] have shown that palonosetron causes a persistent inhibition 
of 5-HT
3
R function as reflected by a near complete suppression of 5-HT-evoked extracellu-
lar Ca2+ influx. They have further demonstrated that palonosetron can prevent enhancement 
of substance P-induced intracellular Ca2+ release in response to serotonin in NG108–15 cells 
expressing both 5-HT
3
Rs and NK
1
Rs [85]. Our Ca2+ monitoring studies performed on acutely-
prepared least shrew brainstem slices also demonstrate that palonosetron can abolish enhance-
ment of intracellular Ca2+ levels in brainstem slices evoked by the selective 5-HT
3
R agonist 
2-Methyl-5-HT [25]. The latter finding provides more relevant ex-vivo evidence for the Ca2+-
modulating antiemetic effect of palonosetron in a vomit-competent species. The role of netu-
pitant in suppression of substance P-evoked enhancement of intracellular Ca2+ levels has also 
been demonstrated via Ca2+ mobilization assays in vitro in CHO cells expressing the human 
NK
1
Rs. Moreover, pronetupitant, an intravenous alternative to the oral netupitant, appears to 
be more potent than netupitant in both in vitro Ca2+ measurement studies and in vivo animal 
behavioral evaluations of substance P in rats [86]. In addition, another clinically approved NK
1
R 
antagonist antiemetic rolapitant, has been shown to suppress the ability of the selective NK
1
R 
agonist GR73632 to evoke intracellular Ca2+ release [9, 87–89]. The discussed findings clearly 
suggest that Ca2+ is a major player in the initiation of vomiting evoked by diverse emetogens.
3.2. Cannabinoid CB
1
 receptor agonists
Before the introduction of first generation 5-HT
3
R antagonists, several phyto- and synthetic 
cannabinoids including dronabinol (delta-9-tetrahydrocannabinol, Δ9-THC (Figure 2)), 
levonantradol and nabilone, were evaluated in cancer patients for suppression of chemo-
therapy-induced nausea and vomiting that were not effectively controlled by other available 
antiemetics [2, 90]. Cannabinoids are increasingly being tested as antiemetics against cispla-
tin-induced emesis in animal experiments using house musk shrews [91], ferrets [92], or least 
shrews [73, 93]; nausea-related behavior in rats [91]; radiation-induced emesis in the least 
shrew [94]; as well as both phases of chemotherapy-induced nausea and vomiting in the clinic 
[95–97]. Cannabinoid agonists exert their antiemetic efficacy via direct activation of CB
1
 recep-
tors (CB
1
R) since their antiemetic effects were reversed by CB
1
R antagonists [92, 94, 98–100]. 
Significant evidence for a role for CB
2
Rs in emesis is currently lacking [101]. The presence of 
CB
1
Rs in the brainstem nuclei involved in emesis has been confirmed, with a high density of 
CB
1
R immunoreactivity in the dorsal motor nucleus of the vagus and the medial subnucleus 
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of the nucleus tractus solitarius, a moderate density in the commissural subnucleus of the 
nucleus tractus solitarius, and lower densities in the area postrema and dorsal subnucleus of 
the nucleus tractus solitarius [73, 92]. CB
1
R distribution has been also observed in the myen-
teric plexus of the stomach and duodenum [92]. Furthermore, CB
1
Rs have been localized in 
the myenteric plexus of the rat and guinea pig intestine in nearly all cholinergic neuron ter-
minals [102, 103]. These as well as behavioral evidence [42] suggest that the antiemetic action 
of cannabinoids involve both the central dorsal vagal complex and intestinal emetic loci. In 
addition, primary cultures of guinea-pig myenteric neurons express CB
1
Rs and exogenously 
added cannabinoids suppress their neuronal activity, synaptic transmission and mitochon-
drial transport along axons [104]. Moreover, the CB1/2R agonist WIN55212-2 can suppress intestinal activity since it can attenuate the electrically-evoked contractions of the myenteric 
plexus-longitudinal muscle preparation of the guinea-pig small intestine in a Ca2+-dependent 
and CB
1
R-specific manner [105]. Thus, CB
1
R agonists in the in vivo setting can also suppress 
the gastrointestinal tract motility [104]. Using whole-cell patch-clamp recordings in brainstem 
slices, Derbenev et al. [106, 107] have shown that activation of presynaptic CB
1
Rs in the dorsal 
Figure 4. A schematic explanation of the antiemetic action of cannabinoid CB
1
R agonists from the perspective of Ca2+ 
signaling. Activation of CB
1
R initiates a Gi/o mechanism leading to the downregulation of extracellular Ca2+ influx through 
voltage-gated Ca2+ channels (VGCCs) as well as endoplasmic reticulum (ER) Ca2+ release via ryanodine receptors (RyRs) 
which has the potential to be activated by extracellular Ca2+ entry through VGCCs. The reduction in cytosolic Ca2+ 
attenuates Ca2+-dependent emetic neurotransmitter release, which further results in a reduction in postsynaptic neuronal 
activation, and ultimately suppression of the vomiting behavior [93, 103, 117].
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vagal complex inhibits synaptic transmission to the dorsal motor nucleus of the vagus neu-
rons, which may explain suppression of visceral motor responses caused by cannabinoids.
Furthermore, in the central nervous system CB
1
R stimulation can result in inhibition of Ca2+-
dependent neurotransmitter release from presynaptic nerve terminals which consequently 
leads to inhibition of neurotransmission [108]. In chemotherapy-induced nausea and vomiting, 
the CB
1
R-mediated antiemetic action of cannabinoids appears to be directly related to pre-
synaptic inhibition of release of emetic neurotransmitters from nerve terminals. Figure 4 may 
help to explain the antiemetic action of cannabinoid CB
1
R agonists from the Ca2+ perspective. 
Indeed, the adenylyl cyclase/cyclic AMP (cAMP)/protein kinase A (PKA) signal transduction 
system is a well-established emetic signaling pathway [109]. PKA activation is known to phos-
phorylate both Ca2+ ion channels on plasma membrane and intracellular endoplasmic IP
3
Rs, 
which respectively increase extracellular Ca2+ influx and internal Ca2+ release from the sarco/
endoplasmic reticulum stores [110]. CB
1
Rs are known to be Gi/o-protein coupled receptors 
which mediates inhibition of adenylate cyclase. This inhibition has been proposed to be the fun-
damental reason for CB
1
R agonists attenuating Ca2+-dependent emetic neurotransmitter release 
which would ultimately reduce postsynaptic neuronal activation in both dorsal vagal complex 
and gastrointestinal tract [93, 103]. Moreover, dose-dependent inhibitory action of cannabinoid 
CB
1
R agonists on extracellular Ca2+ influx via a number of voltage-gated Ca2+ channels resid-
ing in the cell membrane including N-type, P/Q type and L-type have been demonstrated in 
multiple experimental systems [111–115]. Additionally, cannabinoid CB
1
R agonists also block 
5-HT
3
Rs in a non-competitive manner and thus prevent extracellular Ca2+ influx [115, 116].
Furthermore, CB
1
R agonists appear to inhibit the intracellular Ca2+ release channels located 
on the sarco/endoplasmic reticulum membrane, RyRs. Ca2+-induced Ca2+ release is a well-
established feature of Ca2+ signal amplification. During neuronal activation, Ca2+-induced Ca2+ 
release Ca2+ signaling involves increased concentration of cytoplasmic Ca2+ via extracellular 
Ca2+ influx through voltage-gated Ca2+ channels (e.g., LTCCs) present on the cell membrane, 
which then causes release of stored intracellular Ca2+ from the sarco/endoplasmic reticulum 
into the cytosol through RyRs [117]. In fact RyRs have a wide distribution in the central ner-
vous system including the brainstem [118]. RyRs not only can regulate Ca2+ homeostasis, but 
also other critical brain functions including neurotransmitter release [117]. Increased serum 
levels of the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α), is associated 
with chemotherapy-evoked vomiting [119]. TNF-α can excite vagal afferent terminals by aug-
menting Ca2+ release from sarco/endoplasmic reticulum stores via sensitization of RyRs which 
subsequently amplifies neurotransmission in the brainstem [15]. Cannabinoid CB
1
R agonists 
prevent the TNF-α-evoked sensitization of RyRs and therefore attenuate intracellular Ca2+ 
release from the sarco/endoplasmic reticulum stores [15]. Peripheral RyRs also play a critical 
role in agonist-evoked Ca2+ oscillations in gut epithelial cells [120]. Therefore, the ability of 
CB
1
R agonists in preventing both extracellular Ca2+ influx as well as intracellular Ca2+ release 
from the sarco/endoplasmic reticulum stores may be the fundamental mechanisms underly-
ing the broad-spectrum antiemetic efficacy of CB
1
R cannabinoid agonists.
3.3. Glucocorticoids
Glucocorticoids, used primarily as anti-allergic and anti-inflammatory drugs. They are also 
effective, either alone or in combination with other antiemetics, for the suppression of nausea 
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and vomiting. Indeed, dexamethasone (Figure 2), one of the clinically used glucocorticoids, is 
effective in reducing both acute and delayed chemotherapy-induced nausea and vomiting, and 
when combined with 5-HT
3
 or neurokinin NK
1
 antagonists, it is utilized in patients receiving 
high emetogenic chemotherapy [6]. Glucocorticoids’ antiemetic effect has been related to its 
inhibitory effects in the following facets: (i) glucocorticoids control the inflammatory response 
involved in mediating chemotherapy-induced nausea and vomiting by reducing the produc-
tion of inflammatory mediators such as cytokines, chemokines, inducible nitric oxide synthase, 
and increasing the gene transcription of anti-inflammatory proteins [6]; (ii) glucocorticoids can 
inhibit 5-HT and substance P release, both of which can evoke emesis [6, 121], (iii) glucocor-
ticoids can cross the blood-brain barrier and can exert direct central inhibitory effects on the 
nucleus tractus solitarius [6], which may be due to a decrease in abnormal elevation of cytosolic 
Ca2+ concentration as well as downstream Ca2+ signals and the maintenance of Ca2+ homeostasis 
within the cell [122], (iv) inhibitory actions of glucocorticoid could also be due to increased 
release of endocannabinoids, anandamide and 2-arachidonoylglycerol, evoked by glucocor-
ticoid administration which will then be followed by subsequent CB
1
R activation as well as 
glucocorticoid facilitation of synaptic γ-aminobutyric acid (GABA) release and suppression of 
glutamate release [123, 124]. The endocannabinoid system is composed of CBRs, endocannabi-
noids and the enzymes involved in their synthesis. Anandamide and 2-arachidonoylglycerol 
are among the well-studied endocannabinoids and endogenous activators of CBRs [125]. The 
role of CB
1
R agonists as antiemetics was discussed in Section 2.2. It has been suggested that 
dexamethasone may decrease motion sickness through modulation of the endocannabinoid/
CB
1
 receptor system on the terminals of the nucleus tractus solitarius neurons that project to the 
output neurons of the DMNV as well as by endocannabinoid/CB
1
 receptor system-mediated 
inhibition of transmitter release from interneurons of the nucleus tractus solitarius [99, 126]. 
Selective elevation of 2-arachidonoylglycerol by inhibition of its major metabolic enzyme 
monoacylglycerol lipase, have been shown to suppress lithium chloride evoked vomiting 
in the house musk shrew (Suncus murinus) [127]. However, intraperitoneal administration 
of the endocannabinoid 2-arachidonoylglycerol can evoke vomiting in the least shrew in a 
dose-dependent manner probably via its rapid metabolism to arachidonic acid which is also a 
potent emetogen in this species [128]. Moreover, the cancer chemotherapeutic agent cisplatin 
can increase 2-arachidonoylglycerol but not anandamide levels in the least shrew brain [129].
4. Perspective in developing new antiemetic candidates
4.1. Antiemetic efficacy of LTCC blockers in the least shrew model of emesis
Nifedipine along with amlodipine, are among the most studied of Ca2+ channels blockers, and 
both belong to the dihydropyridine subgroup of LTCC antagonists. Relative to nifedipine, a fast 
and short-acting LTCC antagonist with a plasma half-life of 1.2 h, amlodipine is slow and longer 
acting, more extensively bound to plasma protein, with a larger volume of distribution, more 
gradual elimination, with a half-life of over 30 h [130–134]. We have evaluated the antiemetic 
efficacy of both nifedipine and amlodipine (Figure 2) by assessing mean emesis frequency and 
the percentage of shrews vomiting, and demonstrated that both LTCC blockers [45, 46] behave 
as broad-spectrum antiemetics when delivered systemically against diverse specific emetogens, 
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including FPL 64176 (10 mg/kg, i.p.), the peripherally-acting and non-selective 5-HT
3
R ago-
nist 5-HT (5 mg/kg, i.p.), the peripherally/centrally-acting and more selective 5-HT
3
R agonist 
2-Methyl-5-HT (5 mg/kg, i.p.), the dopamine D
2
R-preferring agonist quinpirole (2 mg/kg, i.p.), 
the non-selective dopamine D
2
R agonist apomorphine (2 mg/kg, i.p.), the nonselective cho-
linergic agonist pilocarpine (2 mg/kg, i.p.), the M
1
-preferring cholinergic agonist McN-A343 
(2 mg/kg, i.p.), and the selective neurokinin NK
1
R agonist GR73632 (5 mg/kg, i.p.). The vomiting 
behavior was recorded for 30 min. Our results suggest that both amlodipine and nifedipine 
act by suppressing the influx of extracellular Ca2+, thereby delay the onset as well as protect-
ing least shrews from vomiting, further supporting our proposed Ca2+ hypothesis of emesis. 
Nifedipine appears to be more potent than amlodipine against vomiting caused by FPL64176, 
5-HT, 2-Methyl-5-HT, GR73632, quinpirole and McN-A343. These potency disparities could be 
explained in terms of their pharmacokinetic and pharmacodynamic differences [130–139].
Unlike the above tested emetogens which can evoke vomiting within minutes of administra-
tion, cisplatin (10 mg, i.p.) requires more exposure time (30–45 min) to begin to induce emesis 
since only its metabolites are emetogenic. The relative efficacy of amlodipine (5 mg/kg., i.p.) in 
reducing the frequency of cisplatin-evoked early vomiting by 80% compared with the observed 
lack of antiemetic action of nifedipine up to 20 mg/kg [45, 46], could be explained in terms of 
positively charged amlodipine associating more slowly with LTCCs, requiring more exposure 
time not only to reach its sites of action, but also to compensate for its slower receptor binding 
kinetics, which can lead to a more gradual onset of antagonism [140]. In addition, intracere-
broventricular microinjection of another LTCC antagonist, nitrendipine, has been shown to 
attenuate nicotine-induced vomiting in the cat [141], which further supports the discussed 
broad-spectrum antiemetic efficacy of nifedipine and amlodipine as observed in the least shrew 
model. Cisplatin-based chemotherapeutics induce both immediate and delayed vomiting in 
humans and in vomit-competent animals [16, 142, 143]. In the least shrew, cisplatin (10 mg/kg, 
i.p.) causes emesis over 40 h with respective peak early- and delayed-phases occurring at 1–2 
and 32–34 h post-injection [144]. Amlodipine, due to its unique pharmacokinetics, may offer 
practical advantages over other calcium antagonists in cisplatin-evoked delayed emesis.
4.2. Potentiation of antiemetic efficacy of 5-HT
3
R antagonists when combined with 
LTCC blockers
In 1996 Hargreaves and co-workers [20] demonstrated that members of all three major 
classes of LTCC antagonists can prevent the ability of the 5-HT
3
 receptor-selective agonist 
1-(m-chlorophenyl)-biguanide to increase intracellular Ca2+ concentration in cell lines that 
possess either one or both of these two different Ca2+-ion channels. The latter interaction is 
not competitive since the binding site for the different classes of LTCC antagonists appear 
not to be the same as the serotonin 5-HT
3
R binding site itself (i.e., the orthosteric site) but 
instead, is an allosteric site in the 5-HT
3
 receptor channel complex. Furthermore, 5-HT release 
from enterochromaffin cells can be prevented by antagonists of both 5-HT
3
Rs and LTCCs 
[145, 146]. These findings provide possible mechanisms via which antagonists of both LTCCs 
and 5-HT
3
Rs can mutually prevent the biochemical and behavioral effects of their correspond-
ing selective agonists, including the vomiting behavior induced by their corresponding selective 
agonists FPL64176 and 2-Methyl-5-HT as we reported previously [45]. We have further dem-
onstrated that when non-effective antiemetic doses of their selective antagonists (nifedipine 
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and palonosetron, respectively) are combined [45], the combination significantly and in an 
additive manner attenuate both the frequency and the percentage of shrews vomiting in 
response to either FPL 64176 or 2-Methyl-5-HT. Furthermore, although nifedipine alone up to 
20 mg/kg dose failed to protect shrews from acute cisplatin-induced vomiting, its 0.5 mg/kg 
dose, significantly potentiated the antiemetic efficacy of a non-effective (0.025 mg/kg) as well 
as a semi-effective (0.5 mg/kg) dose of palonosetron. In another study we also utilized a com-
bination of non-effective doses of amlodipine (0.5 mg/kg or 1 mg/kg) with a non- or semi-
effective dose of the 5-HT
3
R antagonist palonosetron (0.05 or 0.5 mg/kg) [46]. The combined 
antiemetic doses produced a similar additive efficacy against vomiting induced by either FPL 
64176 or cisplatin. In fact relative to each antagonist alone, the combination was at least 4 
times more potent in reducing the vomit frequency and provided more protection against 
FPL 64176-induced vomiting. The observed additive antiemetic efficacy of a combination of 
5-HT
3
- (and/or possibly NK
1
-) with LTCC-antagonists in the least shrew suggests that such 
a combination should provide greater emesis protection in cancer patients receiving chemo-
therapy in a manner similar to that reported between 5-HT
3
- and NK
1
-receptor antagonists 
both in the laboratory [144, 147] and in the clinic [148]. Although in our investigation, the 
mechanism underlying the additive antiemetic efficacy of combined low doses of LTCC 
antagonists with 5-HT
3
R antagonists was not directly studied, the published literature points 
to their interaction at the signal transduction level involving Ca2+ [20, 149, 150].
4.3. Clinical use of LTCC blockers as anti-nausea/antiemetic medication
There are several published clinical case reports that demonstrate Ca2+ channel blockers 
may provide protection against several causes of nausea and vomiting. The LTCC antago-
nist flunarizine (Figure 2) was shown to reduce cyclic vomiting on acute basis in one patient 
[151] and prophylactically in 8 other patients [152]. Gabapentin is a gamma-aminobutyric 
acid (GABA) analog and is predominantly used in the clinic for the management of pain 
[3]. Gabapentin binds to the alpha-2/delta auxiliary subunits of voltage-gated Ca2+ channels 
(VGCCs) (i.e., LTCCs), and exerts inhibitory actions on trafficking and activation kinetics of 
VGCCs [153] (Figure 2). Moreover, several other reports indicate that gabapentin can also be 
used as a well-tolerated, less-expensive and promising anti-nausea and antiemetic agent in 
diverse conditions including: postoperative nausea and vomiting [154, 155], moderately or 
highly emetogenic chemotherapy-induced nausea and vomiting, particularly effective against 
delayed chemotherapy-induced nausea and vomiting [156], and both acute and delayed nau-
sea induced by chemotherapy [157], as well as hyperemesis gravidarum [158]. When com-
bined with dexamethasone, gabapentin can also significantly reduce the 24-h incidence of 
postoperative nausea and vomiting [159]. Alpha-2/delta subunits of VGCCs control transmit-
ter release and further facilitate excitatory transmission [153]. Gabapentin’s interaction with 
neuronal alpha-2/delta subunits of VGCCs and subsequent downregulation of neuronal Ca2+ 
signaling in emesis relevant sites, such as the dorsal vagal complex, is postulated to play a 
critical role in its anti-nausea and anti-vomiting effects [3].
4.4. Intracellular Ca2+ release channels: possible targets for suppression of emesis
A functional and physical linkage between LTCCs and RyRs appears to exist and plays an impor-
tant role in intracellular Ca2+ release following voltage-dependent Ca2+ entry through LTCCs 
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during neuronal depolarization to generate a transient increase in cytosolic Ca2+ [160–162]. 
Physical attachment of IP
3
Rs to plasma membrane Ca2+ influx channels through conformational 
coupling has also been proposed as one of the mechanisms connecting depletion of internal 
Ca2+ stores with stimulation of extracellular Ca2+ influx [163]. For example, Ca2+ release from 
IP
3
Rs was shown to couple with extracellular Ca2+ influx through LTCCs in non-excitable cells 
such as Jurkat human T lymphocytes [164] and drosophila S2 cells [165], as well as in excitable 
cells such as submucosal neurons in the rat distal colon [166]. We have found that 5-HT
3
R-
mediated vomiting triggered by 5 mg/kg 2-Methyl-5-HT is insensitive to the intracellular Ca2+ 
release channel IP
3
R antagonist 2-APB, but in contrast, was dose-dependently suppressed by 
the RyR antagonist, dantrolene [25]. Furthermore, a combination of the semi-effective doses 
of amlodipine and dantrolene was more potent than each antagonist being tested alone [25]. 
Significant reductions (70–85%) in the frequency of Ca2+ mobilizer thapsigargin-evoked vomit-
ing (see Section 1.2) were observed when shrews were pretreated with antagonists of either 
IP
3
Rs (2-APB at 1 and 2.5 mg/kg, i.p.)- or RyRs (dantrolene at 2.5 and 5 mg/kg, i.p.)-ER luminal 
Ca2+ release channels. Moreover, while a mixture of 2-APB (1 mg/kg) and dantrolene (2.5 mg/kg) 
did not offer additional protection than what was afforded when each drug administered 
alone, a combination of the latter doses of 2-APB plus dantrolene with a partially effective dose 
of nifedipine (2.5 mg/kg), led to a complete elimination of thapsigargin-evoked vomiting [70]. 
In another set of experiments [167], we found that pretreatment with the IP
3
R inhibitor 2-APB 
causes a significant reduction in NK
1
R agonist GR73632-induced emesis, however the RyR 
inhibitor dantrolene did not. Thus, RyRs and IP
3
Rs can be differentially modulated by various 
emetogens and their antagonists provide further efficacy when combined with LTCC antago-
nists (Figure 2). Suppression of Ca2+ release from the sarco/endoplasmic reticulum stores 
through IP
3
Rs and RyRs may be additional targets for the prevention of nausea and vomiting.
4.5. Ca2+-related signaling pathways in emesis
4.5.1. The role of cAMP-PKA in vomiting
In mammals, cyclic AMP (cAMP) is synthesized by 10 adenylate cyclase isoforms [168]. One 
of the best-studied second messenger molecules downstream of selected G-protein coupled 
receptors is cAMP. It is an example of a transient and diffusible second messenger involved 
in signal propagation by integrating multiple intracellular signaling pathways [169]. cAMP 
activates protein kinase A (PKA) which results in phosphorylation of downstream intracel-
lular signals. The adenylyl cyclase/cAMP/PKA signaling pathway can phosphorylate Ca2+ ion-
channels found on the plasma membrane and intracellular IP
3
Rs [110]. These Ca2+ channels 
respectively increase extracellular Ca2+-influx and intracellular Ca2+-release [110]. The emetic 
role of cAMP has been well established (Figure 5), since microinjection of cAMP analogs 
(e.g., 8-bromocAMP) or forskolin (to enhance endogenous levels of cAMP) in the brainstem 
dorsal vagal complex emetic locus area postrema, not only can increase electrical activity of 
local neurons, but also induces vomiting in dogs [170]. Moreover, administration of 8-chlo-
rocAMP as a potential chemotherapeutic in cancer patients can evoke nausea and vomiting 
[171]. Furthermore, phosphodiesterase inhibitors (PDEI) such as rolipram prevent cAMP 
metabolism and consequently increase cAMP tissue levels, which leads to excessive nausea 
and vomiting in humans [172]. In fact, one major side-effect of older PDEIs is excessive nausea 
and vomiting which often precludes their use in the clinical setting [173]. In addition, we have 
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Figure 5. Summarized behavioral and biochemical evidence for intracellular signaling molecules (cAMP, PKA, CaMKII, 
ERK1/2, PKC) related to emesis based on the least shrew emesis model. First, cyclic AMP (cAMP) is synthesized by 
adenylate cyclase and cAMP activates protein kinase A (PKA) [110, 168]. The adenylyl cyclase/cAMP/PKA signaling 
pathway can mediate vomiting. Indeed, increased levels of endogenous cAMP can evoke vomiting in animal models 
[109, 170] as well as humans [171–173], which can be prevented by adenylate cyclase inhibitor SQ22536 [109]. Evoked 
PKA-phosphorylation is associated with peak vomit frequency during both immediate- and delayed-phases of vomiting 
caused by cancer chemotherapeutics including cisplatin and cyclophosphamide in the least shrew [109, 144, 149]. In 
addition, Ca2+/calmodulin kinase IIα (CaMKIIα) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) 
phosphorylation in the least shrew brainstem were elevated in vomiting evoked by the 5-HT
3
R agonist 2-Methyl-5-HT 
[46], thapsigargin [70], or the selective NK
1
R agonist GR73632 [167]. Phosphorylation of protein kinase Cα/βII (PKCα/
βII) and ERK1/2 in least shrew brainstem were also upregulated in the vomiting induced by cisplatin [144, 149].
demonstrated that increased brain cAMP levels evoke vomiting which can be prevented by 
SQ22536 (Figure 5), an inhibitor of adenylyl cyclase [109]. Moreover, PKA-phosphorylation is 
associated with peak vomit frequency during both immediate- and delayed-phases of vomit-
ing caused by either cisplatin or cyclophosphamide in the least shrew [109, 144, 149] (Figure 5).
4.5.2. Activation and inhibition of CaMKII, ERK1/2, PKC, and Akt are correspondingly linked 
to emesis induction and prevention
Vomit-associated Ca2+ mobilization as well as time-dependent Ca2+/calmodulin kinase IIα 
(CaMKIIα) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) phosphoryla-
tion in the least shrew brainstem occurs: (i) following 5-HT
3
R-evoked vomiting caused by its 
selective agonist 2-Methyl-5-HT [46], (ii) thapsigargin-induced emesis in the least shrew [70], as 
well as (iii) NK
1
R-mediated vomiting evoked by the selective NK
1
R agonist GR73632 in the least 
shrew [167] (Figure 5). Our additional behavioral evidence that inhibitors of CaMKII or ERK1/2 
attenuate the evoked emesis provides further credence for involvement of CaMKII and ERK1/2 
downstream of the discussed emetic receptors/effectors. Furthermore, other published evi-
dence support phosphorylation of protein kinase Cα/βII (PKCα/βII) and ERK1/2 in least shrew 
brainstem are associated with cisplatin-induced emesis [144, 149] (Figure 5). In fact significant 
upregulation of ERK1/2 phosphorylation occurs with peak vomit frequency during both the 
immediate and delayed phases of emesis caused by cisplatin in the least shrew [144, 149].
It has been suggested that glucocorticoids’ antiemetic efficacy could be due to their anti-
inflammatory effects [174] probably via a reduction in the synthesis of prostaglandins and 
leukotrienes [175], both of which can be increased during chemotherapy [6]. Although not 
all, but several prostaglandins (e.g., PGE2 and PGF2a) and cysteinyl leukotrienes (e.g., LTC4 
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and LTD4), appear to be potent emetogens [72, 149, 176, 177]. Our findings demonstrate that unlike other leukotrienes (e.g., LTA4, LTB4 and LTF4), the above discussed leukotrienes are effective emetogens with the following potency order: LTC4 = LTD4 > LTE4. Regarding LTC4, the evoked vomiting was shown to be suppressed in a dose-dependent manner in the 
least shrew by the antiasthmatic drug pranlukast, the corresponding cysteinyl leukotrienes 
receptor 1 (CysLT1R) antagonist [72]. Although not available in the USA, the cost of other 
members of this class of drugs (montelukast and Zafirlukast) that are sold in the USA is 
less than one dollar per pill. Based on pranlukast’s efficacy against LTC4-induced vomiting [72], we envisaged it may have potential utility against cisplatin-evoked emesis. Our most 
recent publication [178] shows the potential of pranlukast (currently used for the treatment 
of various respiratory disorders including asthma), as a new class of antiemetic for the 
suppression of the acute- and delayed- phases of cisplatin-evoked vomiting in the least 
shrew. An intraperitoneal (i.p.) dose of 10 mg/kg pranlukast by itself significantly reduced 
the mean frequency of vomits by 70% and fully protected 46% of least shrews during the 
delayed-phase of cisplatin (10 mg/kg, i.p.)-evoked vomiting. Although pranlukast tended 
to substantially reduce both the mean frequency of vomits and the number of shrews vom-
iting during the early-phase, these reductions failed to attain significance. When pranlukast 
was combined with a first (tropisetron)- or a second (palonosetron)-generation 5-HT
3
R 
antagonist, it potentiated their antiemetic efficacy during both acute- and delayed-phases 
of cisplatin-evoked vomiting. Moreover, pranlukast potentiated the antiemetic efficacy of 
serotonin 5-HT
3
 receptor antagonists, tropisetron and palonosetron, against chemotherapy-
induced nausea and vomiting. In fact per hour efficacy antiemetic profile of pranlukast 
combined with palonosetron or tropisetron during both phases of chemotherapy-induced 
nausea and vomiting in the least shrew resembles those of: (i) the NK
1
 receptor antagonist 
netupitant (5 mg/kg) plus palonosetron (0.1 mg/kg) in the same species [144]; (ii) netupi-
tant plus ondansetron in ferrets [179]; and (iii) ondansetron plus aprepitant in combination 
with dexamethasone in ferrets [179]; and (iv) palonosetron plus netupitant in combina-
tion with dexamethasone in ferrets [179]. If analogs of pranlukast such as montelukast and 
zafirlukast can also provide similar antiemetic potential, then clinical trials should be initi-
ated since this class of drugs are relatively inexpensive than available effective antiemetic 
regimens against chemotherapy-induced nausea and vomiting. Our related biochemical 
data indicates the mechanisms of antiemetic action of pranlukast are linked to suppression 
of cisplatin-elicited PKCα/βII, ERK1/2 and PKA activation (phosphorylation) in the least 
shrew brainstem [178]. Moreover, suppression of these signaling molecules may be shared 
in the anti-inflammatory signaling pathway of pranlukast.
When antiemetic mechanism of action of pranlukast against LTC4-induced vomiting or 
cisplatin-induced responses is discussed, Ca2+ is also an essential element. Montelukast and 
pranlukast were found to inhibit nucleotide-induced Ca2+ mobilization in a human monocyte-
macrophage-like cell line, DMSO-differentiated U937 [180]. CysLT1 receptors belonging to 
the rhodopsin family of the G protein-coupled receptor genes respond to LTD4 with a strong 
increase in cytosolic Ca2+ concentration partially sensitive to pertussis toxin, and with the 
activation of the Ras-MAPK cascade totally dependent upon Gi/o [144]. These signaling effects were totally inhibited by various specific CysLT1-receptor antagonists, and CysLT1 antago-
nists inhibit both the P2Y agonist-induced activation of phospholipase C and intracellular 
Ca2+ mobilization [144].
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5. Conclusion
Chemotherapy-induced nausea and vomiting is a particularly distressing side-effect of 
chemotherapeutics for oncology patients both physically and psychologically. The use of 
5-HT
3
R antagonists combined with NK
1
R antagonists, has enhanced physician’s ability to 
further suppress nausea, the rates of acute- and delayed-vomiting in cancer patients receiving 
chemotherapy. In addition to the commonly reported adverse effects of these agents (includ-
ing headache, diarrhea, constipation, hiccups, and fatigue), many patients still experience 
nausea and delayed vomiting [181–183]. Furthermore, the use of second generation 5-HT
3
R 
and NK
1
R antagonists for the prevention of chemotherapy-induced nausea and vomiting 
is currently cost-prohibitive for most patients in the world. Mechanisms that cause nausea 
are only partially understood and probably in part overlap with those of vomiting. There 
are still unmet needs for newer and less expensive therapeutic options to improve the treat-
ment across the entire spectrum of chemotherapy-induced nausea and vomiting. Additional 
studies should involve combinations of agents that inhibit other neurotransmitter systems 
involved in nausea and vomiting.
As concluded in Figure 2, this systematic review shows clear evidence that Ca2+ modulation is 
an important contributor to antiemetic and probably anti-nausea signaling pathways. LTCC 
blockers, antagonists of intracellular IP
3
Rs and RyRs Ca2+ release channels as well as CysLT1R 
antagonists have the potential to provide less expensive (e.g., nifedipine, amlodipine, dan-
trolene, and pranlukast) broad-spectrum antiemetic agents for the clinic against diverse 
causes of nausea and vomiting. The discussed findings from the least shrew should help 
to open new avenues of research in other established animal models of emesis as well as in 
patients, targeting not only the already discussed Ca2+ channels, but also other Ca2+ channels 
that exist on both the plasma membrane and the membranes of intracellular organs such as 
the sarco/endoplasmic reticulum and mitochondria.
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